NASDAQ:PETX - Aratana Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.34 0.00 (0.00 %)
(As of 05/22/2018 05:15 AM ET)
Previous Close$5.34
Today's Range$5.29 - $5.45
52-Week Range$3.67 - $7.67
Volume202,436 shs
Average Volume333,735 shs
Market Capitalization$250.15 million
P/E Ratio-5.51
Dividend YieldN/A
Beta2.88

About Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics logoAratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs. Its licensed products include canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States; AT-003, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats and dogs; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-017, a listeria based antigen delivery system for treating canine lymphoma in dogs; AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications; and AT-008, a therapeutic candidate for treating canine lymphoma in dogs in Europe. In addition, the company develops other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.

Receive PETX News and Ratings via Email

Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PETX
CUSIPN/A
Phone913-353-1000

Debt

Debt-to-Equity Ratio0.15
Current Ratio3.37
Quick Ratio2.82

Price-To-Earnings

Trailing P/E Ratio-5.51
Forward P/E Ratio-9.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.57 million
Price / Sales9.78
Cash FlowN/A
Price / CashN/A
Book Value$1.86 per share
Price / Book2.87

Profitability

EPS (Most Recent Fiscal Year)($0.97)
Net Income$-47,510,000.00
Net Margins-168.26%
Return on Equity-38.97%
Return on Assets-25.37%

Miscellaneous

Employees85
Outstanding Shares46,850,000

Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics (NASDAQ:PETX) released its quarterly earnings data on Tuesday, March, 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.04. The biopharmaceutical company earned $10.46 million during the quarter, compared to the consensus estimate of $5.72 million. Aratana Therapeutics had a negative return on equity of 38.97% and a negative net margin of 168.26%. View Aratana Therapeutics' Earnings History.

When is Aratana Therapeutics' next earnings date?

Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Aratana Therapeutics.

What price target have analysts set for PETX?

6 brokers have issued twelve-month target prices for Aratana Therapeutics' stock. Their predictions range from $8.00 to $10.00. On average, they anticipate Aratana Therapeutics' share price to reach $8.8333 in the next year. View Analyst Ratings for Aratana Therapeutics.

What are Wall Street analysts saying about Aratana Therapeutics stock?

Here are some recent quotes from research analysts about Aratana Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (3/7/2018)
  • 2. HC Wainwright analysts commented, "Galliprant Approved in EU; Additional Product Approvals Expected in 2018; Reiterate Buy Galliprant approved for canine osteoarthritis in Europe. On January 11, Aratana announced that the EMA has granted Galliprant marketing approval for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Galliprant is licensed to Elanco, the animal health division of Eli Lilly (LLY; not rated), who has exclusive rights to commercialize the drug globally. Galliprant was first approved in the US in March 2016, and in the nine months ended September 30, 2017, generated approximately $9M in product sales and $4M in license and collaboration revenue for Aratana. Going forward, Elanco has assumed all development, regulatory and manufacturing responsibilities for Galliprant, and we expect the company to launch the drug in Europe in 2Q18." (1/16/2018)

Who are some of Aratana Therapeutics' key competitors?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:
  • Dr. Steven St. Peter, Co-Founder, CEO, Pres & Director (Age 52)
  • Mr. Craig A. Tooman, CFO & Treasurer (Age 52)
  • Mr. Brent A. Standridge, Chief Operating Officer (Age 60)
  • Dr. Ernst Heinen, Chief Devel. Officer (Age 55)
  • Mr. John C. Ayres J.D., Gen. Counsel & Sec.

Has Aratana Therapeutics been receiving favorable news coverage?

News stories about PETX stock have trended somewhat positive this week, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aratana Therapeutics earned a news sentiment score of 0.04 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Aratana Therapeutics' major shareholders?

Aratana Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (12.74%), BlackRock Inc. (6.41%), General American Investors Co. Inc. (3.53%), Millennium Management LLC (2.88%), Massachusetts Financial Services Co. MA (2.20%) and Blair William & Co. IL (1.85%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, Julia A Stephanus and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

Which institutional investors are selling Aratana Therapeutics stock?

PETX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Granite Investment Partners LLC and Sheaff Brock Investment Advisors LLC. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

Which institutional investors are buying Aratana Therapeutics stock?

PETX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, General American Investors Co. Inc., Dimensional Fund Advisors LP, Wells Fargo & Company MN, Jane Street Group LLC, Blair William & Co. IL, NJ State Employees Deferred Compensation Plan and Citadel Advisors LLC. View Insider Buying and Selling for Aratana Therapeutics.

How do I buy shares of Aratana Therapeutics?

Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aratana Therapeutics' stock price today?

One share of PETX stock can currently be purchased for approximately $5.34.

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $250.15 million and generates $25.57 million in revenue each year. The biopharmaceutical company earns $-47,510,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]


MarketBeat Community Rating for Aratana Therapeutics (PETX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  297 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  458
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aratana Therapeutics (NASDAQ:PETX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Aratana Therapeutics in the last 12 months. Their average twelve-month price target is $8.8333, suggesting that the stock has a possible upside of 65.42%. The high price target for PETX is $10.00 and the low price target for PETX is $8.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.603.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.8333$8.8333$8.75$9.00
Price Target Upside: 65.42% upside128.25% upside67.62% upside29.68% upside

Aratana Therapeutics (NASDAQ:PETX) Consensus Price Target History

Price Target History for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ:PETX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2018HC WainwrightSet Price TargetBuy$10.00MediumView Rating Details
3/27/2018Stifel NicolausUpgradeHold ➝ Buy$6.00 ➝ $8.00HighView Rating Details
3/16/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$9.00 ➝ $8.00LowView Rating Details
3/12/2018CL KingUpgradeNeutral ➝ Buy$8.00HighView Rating Details
11/16/2017Jefferies GroupSet Price TargetBuy$9.00N/AView Rating Details
8/25/2017Lake Street CapitalLower Price TargetBuy ➝ Buy$15.00 ➝ $10.00LowView Rating Details
2/9/2017William BlairReiterated RatingOutperformN/AView Rating Details
8/11/2016BarclaysLower Price TargetOverweight$15.00 ➝ $11.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Aratana Therapeutics (NASDAQ:PETX) Earnings History and Estimates Chart

Earnings by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ:PETX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.57)
2019 EPS Consensus Estimate: $0.07
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.20)($0.18)($0.19)
Q2 20182($0.17)($0.15)($0.16)
Q3 20182($0.14)($0.14)($0.14)
Q4 20182($0.11)($0.04)($0.08)
Q1 20192($0.10)$0.25$0.08
Q2 20192($0.03)$0.02($0.01)
Q3 20191($0.01)($0.01)($0.01)
Q4 20191$0.01$0.01$0.01

Aratana Therapeutics (NASDAQ PETX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018($0.18)N/AView Earnings Details
5/3/2018Q1 2018($0.20)($0.19)$6.06 million$4.04 millionViewN/AView Earnings Details
3/13/2018Q4 2017($0.23)($0.19)$5.72 million$10.46 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.24)($0.21)$6.47 million$6.16 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.29)($0.26)$4.50 million$5.16 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.34)($0.34)$3.05 million$3.80 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.42)($0.64)$0.80 million$0.29 millionViewN/AView Earnings Details
11/3/2016Q316($0.48)($0.38)$0.13 million$0.04 millionViewN/AView Earnings Details
8/4/2016Q216$0.24$0.61$15.14 million$38.05 millionViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details
8/12/2014Q215($0.36)($0.32)$0.14 million$0.30 millionViewN/AView Earnings Details
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details
3/13/2014Q414($0.21)$0.40$0.12 millionViewN/AView Earnings Details
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aratana Therapeutics (NASDAQ:PETX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aratana Therapeutics (NASDAQ PETX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 67.06%
Insider Trading History for Aratana Therapeutics (NASDAQ:PETX)
Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ PETX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/30/2018Peter Steven StInsiderSell11,513$5.00$57,565.00View SEC Filing  
1/30/2018Peter Steven StCEOSell19,367$4.77$92,380.59672,259View SEC Filing  
1/11/2018Craig A ToomanInsiderSell30,000$5.27$158,100.0075,024View SEC Filing  
12/1/2017Healthcare Master Fun BroadfinMajor ShareholderSell890,516$5.70$5,075,941.20View SEC Filing  
11/29/2017Healthcare Master Fun BroadfinMajor ShareholderSell116,516$6.53$760,849.48View SEC Filing  
11/10/2017Peter Steven StInsiderSell50,000$7.00$350,000.00529,359View SEC Filing  
10/2/2017Peter Steven StInsiderSell50,000$6.24$312,000.00View SEC Filing  
9/25/2017Brent StandridgeCOOSell10,000$6.11$61,100.0070,267View SEC Filing  
9/15/2017Ernst HeinenInsiderSell10,000$6.25$62,500.00130,994View SEC Filing  
4/17/2017Peter Steven StInsiderSell50,000$5.54$277,000.00582,693View SEC Filing  
1/27/2017Peter Steven StInsiderSell50,000$7.72$386,000.00632,693View SEC Filing  
12/15/2016Peter Steven StInsiderSell50,000$7.63$381,500.00592,793View SEC Filing  
10/3/2016Ernst HeinenInsiderSell10,000$10.00$100,000.00115,494View SEC Filing  
9/9/2016Craig A ToomanInsiderSell30,000$9.25$277,500.0072,424View SEC Filing  
8/9/2016Peter Steven StInsiderSell50,000$9.25$462,500.00642,793View SEC Filing  
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00127,503View SEC Filing  
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00717,793View SEC Filing  
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00125,494View SEC Filing  
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16102,424View SEC Filing  
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.4069,980View SEC Filing  
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.0073,600View SEC Filing  
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.0095,294View SEC Filing  
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aratana Therapeutics (NASDAQ PETX) News Headlines

Source:
DateHeadline
Aratana Therapeutics (PETX) Appoints Craig Barbarosh and Lowell Robinson to Board in Cooperation Agreement with Engaged CapitalAratana Therapeutics (PETX) Appoints Craig Barbarosh and Lowell Robinson to Board in Cooperation Agreement with Engaged Capital
www.streetinsider.com - May 21 at 4:42 PM
Aratana Therapeutics Appoints Craig Barbarosh and Lowell Robinson to its Board of Directors in Cooperation Agreement with Engaged CapitalAratana Therapeutics Appoints Craig Barbarosh and Lowell Robinson to its Board of Directors in Cooperation Agreement with Engaged Capital
finance.yahoo.com - May 21 at 8:56 AM
Breakfast Technical Briefing on BioLine Rx and Three More Biotech StocksBreakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks
finance.yahoo.com - May 17 at 9:16 AM
Activist Fund Engaged Takes New Position in Cross Country HealthActivist Fund Engaged Takes New Position in Cross Country Health
www.thestreet.com - May 16 at 9:19 AM
Aratana Therapeutics (PETX) Upgraded to "Buy" by BidaskClubAratana Therapeutics (PETX) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - May 10 at 7:57 PM
Aratana Therapeutics (PETX) Given Consensus Recommendation of "Buy" by AnalystsAratana Therapeutics (PETX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 10 at 3:00 PM
 Brokerages Anticipate Aratana Therapeutics (PETX) Will Post Quarterly Sales of $4.72 Million Brokerages Anticipate Aratana Therapeutics (PETX) Will Post Quarterly Sales of $4.72 Million
www.americanbankingnews.com - May 10 at 4:18 AM
Aratana Therapeutics (PETX) Given a $10.00 Price Target by HC Wainwright AnalystsAratana Therapeutics (PETX) Given a $10.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 8 at 2:28 PM
-$0.17 Earnings Per Share Expected for Aratana Therapeutics (PETX) This Quarter-$0.17 Earnings Per Share Expected for Aratana Therapeutics (PETX) This Quarter
www.americanbankingnews.com - May 8 at 11:43 AM
Edited Transcript of PETX earnings conference call or presentation 4-May-18 12:30pm GMTEdited Transcript of PETX earnings conference call or presentation 4-May-18 12:30pm GMT
finance.yahoo.com - May 5 at 9:21 AM
[$$] Engaged Capital Seeks Seats on Aratana Therapeutics Board[$$] Engaged Capital Seeks Seats on Aratana Therapeutics Board
finance.yahoo.com - May 5 at 9:21 AM
Aratana Therapeutics (PETX) Releases  Earnings Results, Beats Estimates By $0.01 EPSAratana Therapeutics (PETX) Releases Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 4 at 5:58 PM
Aratana: 1Q Earnings SnapshotAratana: 1Q Earnings Snapshot
www.cnbc.com - May 4 at 9:01 AM
Aratana Therapeutics Reports First Quarter 2018 Financial ResultsAratana Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 4:43 PM
Insider Selling: Aratana Therapeutics (PETX) Insider Sells 11,513 Shares of StockInsider Selling: Aratana Therapeutics (PETX) Insider Sells 11,513 Shares of Stock
www.americanbankingnews.com - April 30 at 10:10 PM
Aratana Therapeutics (PETX) Scheduled to Post Quarterly Earnings on MondayAratana Therapeutics (PETX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 9:40 AM
$6.06 Million in Sales Expected for Aratana Therapeutics Inc (PETX) This Quarter$6.06 Million in Sales Expected for Aratana Therapeutics Inc (PETX) This Quarter
www.americanbankingnews.com - April 23 at 4:19 AM
 Analysts Expect Aratana Therapeutics Inc (PETX) to Announce -$0.18 Earnings Per Share Analysts Expect Aratana Therapeutics Inc (PETX) to Announce -$0.18 Earnings Per Share
www.americanbankingnews.com - April 21 at 9:18 AM
Aratana Therapeutics (PETX) Upgraded by Zacks Investment Research to "Buy"Aratana Therapeutics (PETX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 20 at 7:46 AM
Zacks Investment Research Lowers Aratana Therapeutics (PETX) to HoldZacks Investment Research Lowers Aratana Therapeutics (PETX) to Hold
www.americanbankingnews.com - April 18 at 5:18 PM
Aratana Therapeutics (PETX) Downgraded by BidaskClub to HoldAratana Therapeutics (PETX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - April 17 at 1:27 PM
Aratana Therapeutics Inc (PETX) Receives Average Recommendation of "Hold" from AnalystsAratana Therapeutics Inc (PETX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 1:40 PM
Aratana Therapeutics (PETX) Stock Rating Lowered by ValuEngineAratana Therapeutics (PETX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 15 at 9:51 AM
Aratana Therapeutics (PETX) Downgraded by BidaskClub to "Sell"Aratana Therapeutics (PETX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 14 at 4:46 PM
Aratana Therapeutics (PETX) Rating Lowered to Strong Sell at BidaskClubAratana Therapeutics (PETX) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - April 12 at 6:14 PM
Aratana Therapeutics to Report First Quarter 2018 Financial ResultsAratana Therapeutics to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 12 at 9:53 AM
Engaged Capital Nominates Three to ARATANA THERAPEUTICs (PETX) BoardEngaged Capital Nominates Three to ARATANA THERAPEUTIC's (PETX) Board
www.streetinsider.com - April 6 at 9:24 AM
Aratana Therapeutics (PETX) Confirms Receipt of Board Nominations from Engaged CapitalAratana Therapeutics (PETX) Confirms Receipt of Board Nominations from Engaged Capital
www.streetinsider.com - April 5 at 4:43 PM
-$0.18 Earnings Per Share Expected for Aratana Therapeutics Inc (PETX) This Quarter-$0.18 Earnings Per Share Expected for Aratana Therapeutics Inc (PETX) This Quarter
www.americanbankingnews.com - April 4 at 9:33 AM
Aratana Therapeutics (PETX) Stock Rating Upgraded by Zacks Investment ResearchAratana Therapeutics (PETX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 31 at 8:52 PM
Aratana Therapeutics (PETX) and The Competition Financial ContrastAratana Therapeutics (PETX) and The Competition Financial Contrast
www.americanbankingnews.com - March 31 at 5:10 PM
Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in SessionAratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session
finance.yahoo.com - March 28 at 9:20 AM
Pre-Open Movers 03/27: (ATRS) (PETX) (RHT) Higher; (LFIN) (GERN) (OSTK) Lower (more...)Pre-Open Movers 03/27: (ATRS) (PETX) (RHT) Higher; (LFIN) (GERN) (OSTK) Lower (more...)
www.streetinsider.com - March 27 at 4:40 PM
Pet Therapeutic Entyce Can Drive Aratana Higher, Stifel Says In UpgradePet Therapeutic Entyce Can Drive Aratana Higher, Stifel Says In Upgrade
finance.yahoo.com - March 27 at 4:40 PM
Aratana Therapeutics (PETX) Lifted to "Buy" at Stifel NicolausAratana Therapeutics (PETX) Lifted to "Buy" at Stifel Nicolaus
www.americanbankingnews.com - March 27 at 10:07 AM
Aratana Therapeutics Inc (PETX) Receives Average Rating of "Hold" from BrokeragesAratana Therapeutics Inc (PETX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 21 at 1:44 PM
Aratana Therapeutics (PETX) Given a $10.00 Price Target at HC WainwrightAratana Therapeutics (PETX) Given a $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 19 at 5:02 PM
Q1 2018 Earnings Forecast for Aratana Therapeutics Inc Issued By William Blair (PETX)Q1 2018 Earnings Forecast for Aratana Therapeutics Inc Issued By William Blair (PETX)
www.americanbankingnews.com - March 19 at 1:52 AM
Edited Transcript of PETX earnings conference call or presentation 14-Mar-18 12:30pm GMTEdited Transcript of PETX earnings conference call or presentation 14-Mar-18 12:30pm GMT
finance.yahoo.com - March 18 at 9:02 AM
Aratana Therapeutics Inc (PETX) Expected to Announce Earnings of -$0.20 Per ShareAratana Therapeutics Inc (PETX) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - March 18 at 8:46 AM
Aratana Therapeutics (PETX) PT Lowered to $8.00Aratana Therapeutics (PETX) PT Lowered to $8.00
www.americanbankingnews.com - March 16 at 11:34 AM
Aratana Therapeutics (PETX) CEO Steven St. Peter on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaAratana Therapeutics' (PETX) CEO Steven St. Peter on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 14 at 6:10 PM
Aratana raises $11.7M despite aborted stock offeringAratana raises $11.7M despite aborted stock offering
finance.yahoo.com - March 14 at 6:10 PM
Aratana Therapeutics Q4 Earnings PreviewAratana Therapeutics Q4 Earnings Preview
finance.yahoo.com - March 14 at 9:55 AM
Aratana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsAratana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 14 at 9:55 AM
When Can We Expect A Profit From Aratana Therapeutics Inc (NASDAQ:PETX)?When Can We Expect A Profit From Aratana Therapeutics Inc (NASDAQ:PETX)?
finance.yahoo.com - March 13 at 9:18 AM
Aratana Therapeutics (PETX) Upgraded by CL King to BuyAratana Therapeutics (PETX) Upgraded by CL King to Buy
www.americanbankingnews.com - March 12 at 9:22 PM
Is a Surprise Coming for Aratana Therapeutics (PETX) This Earnings Season?Is a Surprise Coming for Aratana Therapeutics (PETX) This Earnings Season?
www.zacks.com - March 9 at 9:30 AM
Aratana Therapeutics (PETX) Lifted to Hold at Zacks Investment ResearchAratana Therapeutics (PETX) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - March 7 at 11:33 AM
General American Investors Co. Inc. Grows Stake in Aratana Therapeutics Inc (PETX)General American Investors Co. Inc. Grows Stake in Aratana Therapeutics Inc (PETX)
www.americanbankingnews.com - March 6 at 9:04 AM

SEC Filings

Aratana Therapeutics (NASDAQ:PETX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aratana Therapeutics (NASDAQ:PETX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aratana Therapeutics (NASDAQ PETX) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.